MarketBeat on MSN4d
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
Beijing accused the United States on Friday of exerting "tariff pressure and blackmail" after President Donald Trump's latest ...
OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
December 16, 2024 Regeneron settles patent lawsuit over protein for testing COVID-19 treatments Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its ...
Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...
Sanofi and Regeneron’s blockbuster biologic Dupixent ... in elderly adults – as the immune system mistakenly attacks proteins in the skin’s basement membrane, leading to inflammation ...
It works by blocking certain proteins in the immune system that trigger inflammation and helps to reduce symptoms, including itching, sinus congestion and breathing difficulties. While Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback